Intravenous (IV) Pantoprazole in Erosive Esophagitis
Completed
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 4
2004-07-01
The aim of this study is to examine whether pantoprazole (Protonix) given through continuous
intravenous infusion for 72 hours is superior to Protonix given through once a day IV
injection in the treatment of erosive esophagitis.
Intravenous (IV) Pantoprazole in Erosive Esophagitis
Completed
Emory University
Phase 4
2004-07-01
The aim of this study is to examine whether pantoprazole (Protonix) given through continuous
intravenous infusion for 72 hours is superior to Protonix given through once a day IV
injection in the treatment of erosive esophagitis.
Study of Intragastric pH Profile After 5 Days Pantoprazole 40 mg iv Followed by Oral Esomeprazole 40 mg po or Oral Pantoprazole 40 mg po
Completed
AstraZeneca
Phase 4
2004-09-01
This Phase IV study is intended to compare intragastric acid suppression of oral esomeprazole
(NEXIUM ® Delayed-Release Capsules) with that of oral pantoprazole (PROTONIX ® Delayed
Release Tablets ), in subjects who continue to require acid-suppressive therapy following a
course of intravenous (iv) pantoprazole (PROTONIX ® I.V. for Injection).
A Randomized, Open-Label, Comparative 3-Way Treatment Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40mg, Lansoprazole 30mg, and Pantoprazole 40mg at Steady State in NSAID-Using Patients
Completed
AstraZeneca
Phase 4
2004-06-01
This study looks at controlling intragastric pH following administration of esomeprazole 40
mg, lansoprazole 30 mg and pantoprazole 40 mg taken orally, once daily in patients taking
either non-selective or cyclooxygenase-2 (COX-2) selective nonsteroidal anti-inflammatory
drugs (NSAIDs).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
